摘要
目的评价炎性细胞因子白细胞介素（IL）6与肝细胞癌的相关性。方法检索Pub Med、ISI web of knowledge、中国生物医学文献数据库和中国期刊全文数据库,将定量检测肝癌患者血清或血浆中IL-6含量的病例对照试验纳入本研究,采用Meta分析法进行定量综合分析。结果纳入的25项研究分成3组分别进行Meta分析：肝癌和正常对照、肝癌和肝硬化以及肝癌和慢性肝炎。肝癌患者血清中IL-6水平显著高于健康人群[25篇,标准化均数差（SMD）为5.02,95%可信区间（95%CI）：4.13～5.91,Z=11.05,P〈0.000 1]、肝硬化患者（15篇,SMD=2.36,95%CI：1.54～3.19,Z=5.60,P〈0.000 1）和肝炎患者（7篇,SMD=2.63,95%CI：1.24～4.03,Z=3.69,P=0.000 2）。结论炎症介质IL-6可能在肝癌发生发展中发挥重要作用。
Objective To evaluate the correlation between interleukin（ IL） 6 and primary hepatocellular carcinoma（ HCC）. Methods Case- control studies that included quantitative data on plasma or serum IL- 6 levels of patients with HCC were identified from Pub Med,ISI Web of Knowledge,CBM,and CNKI. A meta- analysis was performed to quantitatively and comprehensively analyze data. Results Twenty- five studies were included and the meta- analysis was conducted separately for 3 groups： HCC vs controls,HCC vs liver cirrhosis,and HCC vs hepatitis. The serum IL- 6 levels of patients with HCC were significantly higher than those of healthy controls（ 25 studies,standardized mean difference（ SMD） 5. 02,95% CI： 4. 13- 5. 91,Z = 11. 05,P〈0. 000 1）,patients with liver cirrhosis（ 15 studies,SMD =2. 36,95% CI： 1. 54- 3. 19,Z = 5. 60,P〈0. 000 1）,and patients with hepatitis（ 7 studies,SMD = 2. 63,95% CI： 1. 24- 4. 03,Z =3. 69,P = 0. 000 2）. Conclusion The inflammatory mediator,IL- 6,may play an important role in the development and progression of HCC.
出处
《临床肝胆病杂志》
CAS
2015年第6期936-942,共7页
Journal of Clinical Hepatology
基金
国家自然科学基金(81372264)
